kanamycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 1519 59-01-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • kanamycin monosulfate
  • kanamycin a
  • kanamycin
  • kanacin
  • kanamycin sulfate
  • Kanamycin A sulfate
Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.
  • Molecular weight: 484.50
  • Formula: C18H36N4O11
  • CLOGP: -3.88
  • LIPINSKI: 2
  • HAC: 15
  • HDO: 11
  • TPSA: 282.61
  • ALOGS: -0.72
  • ROTB: 6
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 g O
1 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 90 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 30.96 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 1 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.26 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.99 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.10 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 52 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK4,CDK5,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK1,NTRK2,PDK2,PDK4,PRKDC,TEK 21
kinase-selectivity-class CHUK,MAP2K6,PDK1 3
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.65

Approvals:

DateAgencyCompanyOrphan
Feb. 13, 1973 FDA APOTHECON

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug resistance 96.42 66.21 19 121 30430 90597877

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug resistance 109.60 47.30 27 325 56347 110532600

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A07AA08 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
INTESTINAL ANTIINFECTIVES
Antibiotics
ATC J01GB04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
AMINOGLYCOSIDE ANTIBACTERIALS
Other aminoglycosides
ATC S01AA24 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antibiotics
FDA CS M0000946 Aminoglycosides
FDA EPC N0000175477 Aminoglycoside Antibacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011500 Protein Synthesis Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:176497 geroprotector
CHEBI has role CHEBI:76969 bacterial metabolite

Related Drugs by ATC class:

A07AA Antibiotics 12 drugs
amphotericin BcolistinfidaxomicinnatamycinneomycinnystatinparomomycinPolymyxin Brifamycinrifaximinstreptomycinvancomycin
J01GB Other aminoglycosides 12 drugs
amikacinarbekacinbekanamycindibekacingentamicinisepamicinneomycinnetilmicinplazomicinribostamycinsisomicintobramycin
S01AA Antibiotics 27 drugs
amikacinampicillinazidamfenicolazithromycinbacitracinbenzylpenicillincefmenoximecefuroximechloramphenicolchlortetracyclinedibekacindihydrostreptomycin show all 27 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Meningitis indication 7180009 DOID:9471
Bacterial septicemia indication 10001005 DOID:0040085
Infection of skin AND/OR subcutaneous tissue indication 19824006
Bacterial pneumonia indication 53084003 DOID:874
Urinary tract infectious disease indication 68566005
Cholangitis indication 82403002 DOID:9446
Infection of bone indication 111253001
Infectious disease of abdomen indication 128070006
Infectious disorder of joint indication 363162000
Burn Wound Infections indication
Preoperative Bowel Preparation indication
Acute tuberculosis off-label use 25629007
Pulmonary tuberculosis off-label use 154283005 DOID:2957
Hypocalcemia contraindication 5291005
Parkinsonism contraindication 32798002
Dehydration contraindication 34095006
Tinnitus contraindication 60862001
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Pregnancy, function contraindication 289908002
Vertigo contraindication 399153001
Disorder of the 8th Cranial Nerve contraindication
Infant Botulism contraindication




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Bacterial infections Indication
Dogs Bacterial infections Indication

🐶 Veterinary products

ProductApplicantIngredients
Kantrim 200 Zoetis Inc. 1
Amforol Suspension Zoetis Inc. 3
Kantrim Ophthalmic Ointment Zoetis Inc. 1
Amforol Veterinary Oral Tablets Zoetis Inc. 3
Kantrim Ophthalmic Solution Zoetis Inc. 1
Kanfosone Ointment Zoetis Inc. 3
Amphoderm Ointment Zoetis Inc. 3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.29 acidic
pKa2 13.57 acidic
pKa3 7.97 Basic
pKa4 7.46 Basic
pKa5 6.99 Basic
pKa6 5.55 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Gap junction beta-2 protein Ion channel IC50 5.03 CHEMBL
Gap junction alpha-1 protein Ion channel IC50 4.32 CHEMBL
Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B) Enzyme Km 5.68 WOMBAT-PK
3-oxoacyl-[acyl-carrier-protein] synthase 3 Enzyme IC50 5.17 CHEMBL

External reference:

IDSource
4019795 VUID
N0000147884 NUI
D00866 KEGG_DRUG
8063-07-8 SECONDARY_CAS_RN
25389-94-0 SECONDARY_CAS_RN
4018142 VANDF
4019795 VANDF
C0022487 UMLSCUI
CHEBI:6104 CHEBI
KAN PDB_CHEM_ID
CHEMBL1384 ChEMBL_ID
CHEMBL1446 ChEMBL_ID
CHEMBL223520 ChEMBL_ID
D007612 MESH_DESCRIPTOR_UI
DB01172 DRUGBANK_ID
12132 IUPHAR_LIGAND_ID
870 INN_ID
RUC37XUP2P UNII
6032 PUBCHEM_CID
1300476 RXNORM
3358 MMSL
4942 MMSL
d00271 MMSL
002772 NDDF
004897 NDDF
387396008 SNOMEDCT_US
71451001 SNOMEDCT_US
8689007 SNOMEDCT_US

Pharmaceutical products:

None